Abstract

The mission of the Vaccinology Core at LMIV is to address the global need for a malaria vaccine by focusing fundamental and clinical research in malaria immunobiology and vaccinology. BSAM2/Alhydrogel+CPG 7909, a vaccine candidate comprised of AMA1-FVO, AMA1-3D7, MSP142-FVO and MSP142-3D7 in equal mass ratio, has been evaluated in a Phase 1 trial in US. Following safety evaluation of the vaccine in US volunteers, the vaccine candidate is being evaluated in adults in a Phase 1b trial in Mali. The vaccine is well tolerated, whereas the immunogenicity and correlation between antibody titers and the in vitro growth inhibitory activities are being analyzed.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI001003-05
Application #
8336226
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2011
Total Cost
$1,260,732
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Zhu, Daming; Huang, Shuhui; McClellan, Holly et al. (2012) Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine 30:189-94
Ellis, Ruth D; Sagara, Issaka; Doumbo, Ogobara et al. (2010) Blood stage vaccines for Plasmodium falciparum: Current status and the way forward. Hum Vaccin 6:
Ellis, Ruth D; Martin, Laura B; Shaffer, Donna et al. (2010) Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 5:e8787
Miura, Kazutoyo; Zhou, Hong; Diouf, Ababacar et al. (2009) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16:963-8
Plassmeyer, Matthew L; Reiter, Karine; Shimp Jr, Richard L et al. (2009) Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J Biol Chem 284:26951-63
Crompton, Peter D; Mircetic, Marko; Weiss, Greta et al. (2009) The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol 182:3318-26
Traore, Boubacar; Koné, Younoussou; Doumbo, Safiatou et al. (2009) The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine 27:7299-303
Ellis, Ruth D; Dicko, Alassane; Sagara, Issaka et al. (2008) Short report: elevated levels of alanine aminotransferase and hepatitis A in the context of a pediatric malaria vaccine trial in a village in Mali. Am J Trop Med Hyg 79:980-2